​​ SAVE-MORE - Anakinra, an IL-1α/β inhibitor in COVID 19 ● | UPDATES IN MEDICINE

​​ SAVE-MORE - Anakinra, an IL-1α/β inhibitor in COVID 19

● Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

● The SAVE-MORE phase 3 study demonstrates the efficacy of anakinra, an IL-1α/β inhibitor, in patients with COVID-19 and high serum levels of soluble plasminogen activator receptor. In anakinra group median decrease of SOFA score on day 7 from baseline was 1 point (OR = 0.63, P = 0.004). Twenty-eight-day mortality decreased (hazard ratio = 0.45, P = 0.045), and hospital stay was shorter.


Join @Updates_in_Medicine